ArticleThe Journal of clinical investigation2016

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.

Mariano G Cardenas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.